With the acceptance that TGFβ inhibitors are likely to be most beneficial in combination therapy as opposed to as a monotherapy, either with immune checkpoint inhibitors or other approaches including anti- angiogenic strategies (not reviewed here), DNA intercalating agents and even with PARP inhibition, the outlook for the expanded use of TGFβ inhibitors in ovarian cancers remains positive. This evidence concerns the gene TGFB1 and ovarian carcinoma.